Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 163   

Articles published

NVS 95.36 -0.24 (-0.25%)
price chart
Novartis AG (ADR) (NVS) To Acquire Spinifex
Novartis AG (ADR) (NYSE:NVS) has announced the acquisition of Spinifex Pharmaceuticals, Inc. The acquisition will allow Novartis to gain access to Spinifex's experimental drugs for chronic pain.
Novartis AG (ADR) (NVS) To Acquire Spinifex For $200 Million  Bidness ETC
Novartis to buy privately held Spinifex for $200 mln  Proactive Investors USA & Canada
Technical Insights on Novartis AG (ADR) (NYSE:NVS)
[Bloomberg] Novartis AG (ADR) (NYSE:NVS)(TREND ANALYSIS) the world's biggest drugmaker by sales, reported first-quarter profit that beat analysts' estimates as the company begins to benefit from a set of transactions that make it smaller and more ...
Novartis AG (ADR) (NVS) Seeks $2-5 Billion Takeover Targets  Bidness ETC
Novartis Posts Higher Q1 Profit  Benzinga
Novartis AG (ADR) (NVS) Looks At Performance Based Pricing System Ahead Of ...
Novartis AG (ADR) (NYSE:NVS) seems to have heard the feelings of a number of people, who were not happy with the higher costs spent towards new drugs.
Novartis AG (ADR) (NYSE:NVS) Adds Spinifex Pharmaceuticals to its Portfolio  WallStreet.org
Novartis AG (ADR) (NVS) Stock Update: Decline Driven By Forex Headwinds
Novartis AG (ADR) (NYSE:NVS) stock has registered a decline of 6.06% over the past three months, aided in large part by the global market chaos that's bogging down the entire healthcare sector's stock performance.
News Recap - Novartis (NVS), China Mobile (CHL), Facebook (FB), General ...  Techsonian (press release)
How Will Novartis AG Fare After Acquisition of MS Drug From GlaxoSmithKline plc
Novartis AG (ADR) (NYSE:NVS) has another victory to add to its long established success story. Today, the company announced its decision to acquire full rights of an investigational drug from GlaxoSmithKline plc (ADR) (NYSE:GSK); as it seeks to extend ...
Novartis AG (ADR) (NYSE:NVS) To Spend $1B On GlaxoSmithKline plc (ADR) (NYSE ...  WallStreet Scope
How Biogen Inc Gained From Novartis AG (ADR) MS Drug Label Update
Novartis AG (ADR) (NYSE:NVS) recently suffered a potential blow to its revenue stream from its top-selling multiple sclerosis drug, Gilenya.
Novartis AG (ADR) Says Cosentyx Can Be A $5 Billion Drug After New Trial Data
Novartis AG (ADR) (NYSE:NVS) has updated its annual sales forecast for its potential blockbuster injectable drug Cosentyx (secukinumab), after new clinical data establishes the drug's long-term benefits in treating psoriatic arthritis.
Novartis' Cosentyx Positive in Psoriatic Arthritis Study - Analyst Blog  Yahoo News
Novartis AG (ADR) (NVS) Q2 Profits Eaten By Strengthening Dollar
Novartis AG (ADR) (NYSE:NVS) announced second-quarter financial results for fiscal'15 before the markets opened today.
Novartis (NVS) Beats on Earnings & Revenues in Q2 - Tale of the Tape  Nasdaq
GlaxoSmithKline plc Deal Unlikely To Help Novartis AG Top Oncology Sales
Novartis AG (ADR) (NYSE:NVS) concluded its three-way asset swap transaction with GlaxoSmithKline plc. (ADR) (NYSE:GSK) in March 2015.
Novartis AG (NVS) Stock Soars On Heart-Failure Drug Approval
The US Food and Drug Administration (FDA) has approved Novartis AG's (ADR) (NYSE:NVS) new heart-failure drug, Entresto, the agency announced in a press release on Tuesday.
Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog  Nasdaq
Novartis Heart Failure Drug Entresto Receives FDA Approval  Zacks.com